Antiviral Activity of Ivermectin Against SARS-CoV-2: An Old-Fashioned Dog with a New Trick—A Literature Review

Scientia Pharmaceutica

Dewi Megawati¹  Wilda Mahdani²  Harapan Harapan²  Mudatsir Mudatsir²  Ichsan Ichsan²  Kuldeep Dhama³  Firzan Nainu⁴  Agung Pranata⁵  Amanda Yufika⁵  Andri Frediansyah⁶ 

[1] Department of Microbiology and Parasitology, Faculty of Medicine and Health Sciences, Warmadewa University, Denpasar 80239, Indonesia;Department of Microbiology, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Aceh 2311, Indonesia;Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh 243122, India;Faculty of Pharmacy, Hasanuddin University, Makassar 90245, Indonesia;Medical Research Unit, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Aceh 23111, Indonesia;Research Division for Natural Product Technology (BPTBA), Indonesian Institute of Sciences (LIPI), Wonosari 55861, Indonesia;

关键词: SARS-CoV-2;    COVID-19;    ivermectin;    treatment;    antiviral;   

DOI  :  10.3390/scipharm88030036

来源: DOAJ

【 摘 要 】

The coronavirus disease 2019 (COVID-19) pandemic is a major global threat. With no effective antiviral drugs, the repurposing of many currently available drugs has been considered. One such drug is ivermectin, an FDA-approved antiparasitic agent that has been shown to exhibit antiviral activity against a broad range of viruses. Recent studies have suggested that ivermectin inhibits the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), thus suggesting its potential for use against COVID-19. This review has summarized the evidence derived from docking and modeling analysis, in vitro and in vivo studies, and results from new investigational drug protocols, as well as clinical trials, if available, which will be effective in supporting the prospective use of ivermectin as an alternative treatment for COVID-19.

【 授权许可】

Unknown